Composition for reducing new-onset diabetes

Abstract

A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.

1 . A pharmaceutical composition for reducing new incidence rate of diabetes due to administration of HMG-CoA RI comprising at least one member selected from the group consisting of icosapentaenoic acid and its pharmaceutically acceptable salts and esters as its effective component. 
     
     
         2 . The pharmaceutical composition according to  claim 1  which is administered to a patient having a serum HDL cholesterol concentration of less than 40 mg/dL. 
     
     
         3 . The pharmaceutical composition according to  claim 1  which is administered to a low HDL cholesterolemia patient. 
     
     
         4 . The pharmaceutical composition according to  claim 2  which is administered to a patient having a serum triglyceride concentration of at least 150 mg/dL. 
     
     
         5 . The pharmaceutical composition according to  claim 2  which is administered to a hypertriglyceridemia patient. 
     
     
         6 . The pharmaceutical composition according to  claim 1  which is administered to a patient administered with HMG-CoA RI having a fasting blood glucose of less than 126 mg/dL. 
     
     
         7 . The pharmaceutical composition according to  claim 1  which is administered to a patient administered with HMG-CoA RI having a fasting blood glucose of at least 110 mg/dL and less than 126 mg/dL. 
     
     
         8 . The pharmaceutical composition according to  claim 1  which is administered to a patient administered with HMG-CoA RI having a fasting blood glucose of at least 100 mg/dL and less than 110 mg/dL. 
     
     
         9 . The pharmaceutical composition according to  claim 1  which is administered to a patient administered with HMG-CoA RI having impaired glucose tolerance or obesity. 
     
     
         10 . The pharmaceutical composition according to  claim 1 , wherein at least one member selected from the group consisting of icosapentaenoic acid and its pharmaceutically acceptable salts and esters is ethyl icosapentate. 
     
     
         11 . A pharmaceutical composition for suppressing increase of blood glucose due to administration of HMG-CoA RI comprising at least one member selected from the group consisting of icosapentaenoic acid and its pharmaceutically acceptable salts and esters as its effective component. 
     
     
         12 . The pharmaceutical composition according to  claim 11  which is administered to a patient having a serum HDL cholesterol concentration of less than 40 mg/dL. 
     
     
         13 . The pharmaceutical composition according to  claim 11  which is administered to a low HDL cholesterolemia patient. 
     
     
         14 . The pharmaceutical composition according to  claim 12  which is administered to a patient having a serum triglyceride concentration of at least 150 mg/dL. 
     
     
         15 . The pharmaceutical composition according to  claim 12  which is administered to a hypertriglyceridemia patient. 
     
     
         16 . The pharmaceutical composition according to  claim 11  which is administered to a patient administered with HMG-CoA RI having a fasting blood glucose of less than 126 mg/dL. 
     
     
         17 . The pharmaceutical composition according to  claim 11  which is administered to a patient administered with HMG-CoA RI having a fasting blood glucose of at least 110 mg/dL and less than 126 mg/dL. 
     
     
         18 . The pharmaceutical composition according to  claim 11  which is administered to a patient administered with HMG-CoA RI having a fasting blood glucose of at least 100 mg/dL and less than 110 mg/dL. 
     
     
         19 . The pharmaceutical composition according to  claim 11  which is administered to a patient administered with HMG-CoA RI having impaired glucose tolerance or obesity. 
     
     
         20 . The pharmaceutical composition according to  claim 11 , wherein at least one member selected from the group consisting of icosapentaenoic acid and its pharmaceutically acceptable salts and esters is ethyl icosapentate.